Sight Sciences, Inc. Common Stock
SGHT US82657M1053
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -48% | -32% | -58% | -29% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Taylor Brenton |
3.37 USD |
591 Sold |
1,992 USD |
06/10/2025 | 06/10/2025 |
| Hayden Jeremy B. CLO |
3.27 USD |
9,731 Sold |
31,820 USD |
03/10/2025 | 03/10/2025 |
| Badawi David CTO |
3.27 USD |
6,033 Sold |
19,728 USD |
03/10/2025 | 03/10/2025 |
| Bauerlein Alison CFO |
3.30 USD |
19,948 Sold |
65,828 USD |
02/10/2025 | 02/10/2025 |
| Badawi Paul CEO |
3.34 USD |
24,441 Sold |
81,633 USD |
01/10/2025 | 01/10/2025 |
| Badawi David CTO |
4.17 USD |
5,679 Sold |
23,704 USD |
03/07/2025 | 03/07/2025 |
| Hayden Jeremy B. CLO |
4.17 USD |
9,160 Sold |
38,234 USD |
03/07/2025 | 03/07/2025 |
| Hayden Jeremy B. CLO |
4.17 USD |
9,160 Sold |
38,234 USD |
03/07/2025 | 03/07/2025 |
| Bauerlein Alison CFO |
4.10 USD |
19,260 Sold |
78,927 USD |
02/07/2025 | 02/07/2025 |
| Link Matthew CCO |
4.10 USD |
4,889 Sold |
20,035 USD |
02/07/2025 | 02/07/2025 |